Thomas Schmidt, 21st.BIO CEO (via 21st.BIO website)
December 23, 2021 10:46 AM EST
Manufacturing

No­vo Hold­ings to help young Dan­ish com­pa­ny with ef­forts to pro­vide scale to start-ups

Josh Sullivan

A Dan­ish bio in­dus­tri­al scale-up com­pa­ny has land­ed an $86 mil­lion in­vest­ment from No­vo Hold­ings, and it’s hop­ing to build on a tech­nol­o­gy base from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times